Block 3

Programme


	Diagnostic procedures
		Diagnosis on lymph node biopsy, including knowledge on immunophenotyping, specific cytogenetics, molecular diagnostics, including gene expression profiling, etc. Daphne De Jong, NL
		Initial work-up (physical examination, bone-marrow biopsy, laboratory and imaging) and establishing the stage of disease, A or B Silvia Montoto, UK
	Principles of treatment
		Chemo- and immuno-chemotherapy, including autologous stem cell transplant Carla Casulo, US
		Principles of radiotherapy Danielle Rodin, CA
		Antibodies, PD1/PDL1 Anastasios Stathis, CH
		Allogeneic stem cell transplant Jakob R. Passweg, CH
		CAR-T cell therapy Alexandros Rampotas, UK
		Targeted treatment with new antibodies, antibody-drug-conjugates, radio-immunotherapy, etc Julie M. Vose, US
		Targeted treatment with new compounds: small molecules beyond antibodies Andrew Davies, UK
	Prognostic and predictive factors
		Staging, Response Assessment and Follow-up of Lymphomas Bruce D. Cheson, US
		Minimal residual disease Davide Rossi, CH
		FLIPI/IPI Laurie H. Sehn, CA
		Molecular prognostic factors Georg Lenz, DE
		Imaging Sally Barrington, UK
	Management of clinical trials
		Introduction to design and interpretation of controlled clinical trials Penelope Bradbury, CA
		Meta-analysis and systematic review Dietrich Rothenbacher, DE
		Planning and performance of clinical trials (introduction to good clinical practice) Anastasios Stathis, CH
		Development of a protocol: from the idea to the protocol writing Anastasios Stathis, CH
		Evaluation and publication of clinical trials Bruce D. Cheson, US
		Sponsor responsibility Cristiana Sessa, CH
		Management of a clinical trial database Liv Meert, BE
		Cost evaluation and control, including funding change to funding and management of clinical trials Gerhard Held, DE
		Transfer of study results into clinical practice James O. Armitage, US
	The challenge of translational research
		Integrating molecular biology with clinical trials Kieron Dunleavy, US
		Management of biobanks Peter Möller, DE

Faculty

James O. Armitage, University of Nebraska Medical Center, Dept. of Oncology and Hematology, Omaha, US
Sally Barrington, St Thomas' Hospital, Nuclear Medicine PET Imaging Centre, London, UK
Penelope Bradbury, Princess Margaret Cancer Centre, Divistion of Medical Oncology and Hematology, Toronto, ON, CA
Carla Casulo, University of Rochester Medical Center, Dept. of Medicine, Hematology/Oncology, Rochester, US
Bruce D. Cheson, The Lymphoma Research Foundation, Research Dept., New York, US
Andrew Davies, General Hospital, Cancer Sciences Division, Somers Cancer Research Building, Southampton, UK
Daphne De Jong, Amsterdam University Medical Centre, Hemato-Pathology Department, Amsterdam, NL
Kieron Dunleavy, National Cancer Institute, Hemato Oncology Dept., Washington, DC, US
Gerhard Held, Saarland University, Hemato Oncology Dept., Kaiserslautern, DE
Georg Lenz, Universitätsklinikum Münster, Translationale Onkologie Dept., Münster, DE
Liv Meert, EORTC, Data Management Dept., Brussels, BE
Peter Möller, Ulm University Medical Center, Institute of Pathology, Ulm, DE
Silvia Montoto, Queen Mary's School, Institute of Cancer, Barts Cancer Institute/ Centre for Haemato-Oncology, London, UK
Jakob R. Passweg, University Hospital Basel, Department of Haematology, Basel, CH
Alexandros Rampotas, Oxford University Hospitals, ., Oxford, UK
Danielle Rodin, Princess Margaret Cancer Centre, Radiation Medicine Program, Toronto, CA
Davide Rossi, Oncology Institue of Southern Switzerland (IOSI), Division of Haematology, Bellinzona, CH
Dietrich Rothenbacher, Ulm University, Institute of Epidemiology and Med. Biometry, Ulm, DE
Laurie H. Sehn, British Columbia Cancer Agency, Centre for Lymphoid Cancer, Vancouver, CA
Cristiana Sessa, Istituto Oncologico della Svizzera Italiana, Gynaecology Dpt., Bellinzona, CH
Anastasios Stathis, Oncology Institute of Southern Switzerland, Div. of Medical Oncology, Bellinzona, CH
Julie M. Vose, University of Nebraska Medical Center, Division of Hematology/Oncology, Omaha, Nebraska, US

Certificate of Competence in Lymphoma - fifth cohort (CCL5)

Programme

Faculty

Who we are

Educational Opportunities

Further projects

Media, Social and Community